De Luca L, Marini M, Gonzini L, Boccanelli A, Casella G, Chiarella F, De Servi S, Di Chiara A, Di Pasquale G, Olivari Z, Caretta G, Lenatti L, Gulizia MM, Savonitto S. Contemporary trends and age-specific sex differences in management and outcome for patients with ST-segment elevation myocardial infarction. J Am Heart Assoc. 2016;5(12):e004202.

Article  Google Scholar 

Meid AD, Quinzler R, Freigofas J, Saum KU, Schöttker B, Holleczek B, et al. Medication underuse in aging outpatients with cardiovascular disease: prevalence, determinants, and outcomes in a prospective cohort study. PLoS ONE. 2015;10(8):e0136339.

Article  Google Scholar 

Martin RC. Disparities in heart failure management in older adults. Curr Geriatr Rep. 2023;12(1):1–6.

Google Scholar 

Bendz B, Aaberge L. Acute coronary syndromes in older patients: does older age matter? Lancet. 2020;396(10251):585–7.

Article  Google Scholar 

Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148(9):e9-119.

Article  Google Scholar 

Damluji AA, Forman DE, Wang TY, Chikwe J, Kunadian V, Rich MW, et al. Management of acute coronary syndrome in the older adult population: a scientific statement from the American Heart Association. Circulation. 2023;147(3):e32-62.

Article  Google Scholar 

Ferreiro JL, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123(7):798–813.

Article  Google Scholar 

Group BMJP. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.

Article  Google Scholar 

Collaboration AT. Collaborative overview of randomised trials of antiplatelet therapy prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308(6921):81–106.

Article  Google Scholar 

Nguyen TNM, Sha S, Chen LJ, Holleczek B, Brenner H, Schöttker B. Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: results from two large cohorts with new-user design. Aliment Pharmacol Ther. 2022;56(2):251–62.

Article  CAS  Google Scholar 

Li L, Geraghty OC, Mehta Z, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390(10093):490–9.

Article  Google Scholar 

Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022;145(3):e18-114.

Google Scholar 

Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524–34.

Article  Google Scholar 

Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023;ehad191.

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

Article  CAS  Google Scholar 

Menichelli M, Neumann FJ, Ndrepepa G, Mayer K, Wöhrle J, Bernlochner I, et al. Age- and weight-adapted dose of prasugrel versus standard dose of ticagrelor in patients with acute coronary syndromes. Ann Intern Med. 2020;173(6):436–44.

Article  Google Scholar 

Savonitto S, Ferri LA, Piatti L, Grosseto D, Piovaccari G, Morici N, et al. Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization. Circulation. 2018;137(23):2435–45.

Article  CAS  Google Scholar 

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

Article  CAS  Google Scholar 

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–800.

Article  Google Scholar 

Szummer K, Montez-Rath ME, Alfredsson J, Erlinge D, Lindahl B, Hofmann R, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome. Circulation. 2020;142(18):1700–8.

Article  CAS  Google Scholar 

Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020;395(10233):1374–81.

Article  CAS  Google Scholar 

Montalto C, Morici N, Munafò AR, Mangieri A, Mandurino-Mirizzi A, D’Ascenzo F, et al. Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials. Eur Heart J - Cardiovasc Pharmacother. 2022;8(1):20–7.

Article  Google Scholar 

Crimi G, Morici N, Ferrario M, Ferri LA, Piatti L, Grosseto D, et al. Time course of ischemic and bleeding burden in elderly patients with acute coronary syndromes randomized to low-dose prasugrel or clopidogrel. J Am Heart Assoc. 2019;8(2):e010956.

Article  CAS  Google Scholar 

Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van ’t Hof AWJ, van der Harst P, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–31.

Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2021;42(14):1289–367.

Article  Google Scholar 

Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747–57.

Article  CAS  Google Scholar 

Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS ONE. 2011;6(9):e24964.

Article  CAS  Google Scholar 

Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(1):83–99.

Article  Google Scholar 

Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–41.

Article  CAS  Google Scholar 

Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103–13.

Article  CAS  Google Scholar 

Angiolillo DJ, Bhatt DL, Cannon CP, Eikelboom JW, Gibson CM, Goodman SG, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2021;143(6):583–96.

Article  CAS  Google Scholar 

Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.

Article  CAS  Google Scholar 

Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–24.

Article  CAS  Google Scholar 

Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–24.

Article  CAS  Google Scholar 

Galli M, Andreotti F, Porto I, Crea F. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. EP Eur. 2020;22(4):538–46.

Joosten LPT, van Doorn S, van de Ven PM, Köhlen BTG, Nierman MC, Koek HL, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation. 2024;149(4):279–89.

CAS  Google Scholar 

Gundersen T, Abrahamsen AM, Kjekshus J, Rønnevik PK. Timolol-related reduction in mortality and reinfarction in patients ages 65–75 years surviving acute myocardial infarction. Prepared for the Norwegian Multicentre Study Group. Circulation. 1982;66(6):1179–84.

The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The beta-blocker pooling project research group. Eur Heart J. 1988;9(1):8–16.

A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA. 1982;247(12):1707–14.

Shavadia JS, Holmes DN, Thomas L, Peterson ED, Granger CB, Roe MT, et al. Comparative effectiveness of β-blocker use beyond 3 years after myocardial infarction and long-term outcomes among elderly patients. Circ Cardiovasc Qual Outcomes. 2019;12(7):e005103.

Article  Google Scholar 

Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Circulation. 2002;106(17):2194–9.

Article  Google Scholar 

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–90.

Gilstrap L, Austin AM, O’Malley AJ, Gladders B, Barnato AE, Tosteson A, et al. Association between beta-blockers and mortality and readmission in older patients with heart failure: an instrumental variable analysis. J Gen Intern Med. 2021;36(8):2361–9.

Article  Google Scholar 

Zullo AR, Lee Y, Daiello LA, Mor V, John Boscardin W, Dore DD, et al. Beta-blocker use in U.S. Nursing home residents after myocardial infarction: a national study. J Am Geriatr Soc. 2017;65(4):754–62.

Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation of β-blockers in patients without heart failure optimally treated after acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2018;11(4):e004356.

Article  Google Scholar 

Misumida N, Harjai K, Kernis S, Kanei Y. Does oral beta-blocker therapy improve long-term survival in ST-segment elevation myocardial infarction with preserved systolic function? A Meta-Analysis J Cardiovasc Pharmacol Ther. 2016;21(3):280–5.

Article  CAS  Google Scholar 

Zhang H, Yuan X, Zhang H, Chen S, Zhao Y, Hua K, et al. Efficacy of long-term β-blocker therapy for secondary prevention of long-term outcomes after coronary artery bypass grafting surgery. Circulation. 2015;131(25):2194–201.

Article  CAS  Google Scholar 

Puymirat E, Riant E, Aissaoui N, Soria A, Ducrocq G, Coste P, et al. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016;20(354):i4801.

Article  Google Scholar 

Huang BT, Huang FY, Zuo ZL, Liao YB, Heng Y, Wang PJ, et al. Meta-analysis of relation between oral β-blocker therapy and outcomes in patients with acute myocardial infarction who underwent percutaneous coronary intervention. Am J Cardiol. 2015;115(11):1529–38.

Article  CAS